David R. Gandara, M.D., UC Davis Comprehensive Cancer Center, discusses how diagnostic and therapeutic changes are happening alongside one another in non-small cell lung cancer.
David R. Gandara, M.D., UC Davis Comprehensive Cancer Center, discusses how diagnostic and therapeutic changes are happening alongside one another in non-small cell lung cancer.
As tumor biology becomes better understood through biopsies and genetic testing, oncologists and patients can form more personalized treatment plans. For example, the mechanism of resistance can be determined through a blood biopsy or a rebiopsy for patients with EGFR- or ALK-positive disease. The results will have a significant impact on the next line of treatment.
Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited
December 7th 2020In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.
Read More
To gain a better understanding of the issues faced by geriatric patients with cancer, and to determine how much of a role nutrition plays in outcomes, Dr. Grant Williams, a geriatrician oncologist and assistant professor at the University of Alabama, Birmingham, worked with colleagues to create a patient-reported assessment tool that bridges the knowledge gap in this patient population.
Read More